Hypertrophic cardiomyopathy (HCM) is a heart-muscle disease characterized by otherwise unexplained myocardial thickening. Some patients have obstruction of the left-ventricular outflow tract (often described as obstructive HCM or HOCM), while others do not. The 2023 ESC cardiomyopathy guidelines emphasize a phenotype- and cause-based approach that includes imaging, genetic and family assessment, symptom management and prevention of complications rather than assuming that every patient with HCM needs the same drug, device or invasive treatment.
Confirm HCM and distinguish it from other causes of ventricular thickening
A specialist center should review whether the hypertrophy represents sarcomeric HCM or another condition that can mimic the phenotype, such as hypertensive remodeling, storage disease or cardiac amyloidosis. The diagnostic pathway can therefore involve more than echocardiography alone.
- Echocardiography with wall thickness and outflow-gradient assessment
- Cardiac MRI when available or clinically useful
- 12-lead and ambulatory ECG
- Exercise or provocation testing when relevant
- Family history of cardiomyopathy or sudden cardiac death
- Genetic testing and counselling when appropriate
- Evaluation for phenocopies when the clinical pattern suggests another disease
Obstructive and non-obstructive HCM are different treatment pathways
Symptoms can arise from outflow obstruction, diastolic dysfunction, ischemia, mitral-valve interaction, atrial fibrillation or progression to heart failure. Treatment therefore depends on the mechanism driving symptoms and not only on the measured wall thickness.
Medical treatment should match symptoms and physiology
Medication can be used to manage symptoms and specific HCM complications, but the exact regimen depends on obstruction, blood pressure, rhythm, ventricular function and other conditions. Disease-specific pharmacologic options may be considered in selected obstructive HCM pathways according to current specialist guidance and availability, but treatment requires individualized monitoring.
Septal-reduction therapy is for selected obstructive HCM
Patients with important symptoms and clinically significant outflow obstruction despite appropriate medical management may be assessed for septal-reduction therapy at an experienced center. Options can include surgical septal myectomy or catheter-based alcohol septal ablation/TASH in selected anatomy. The techniques are not interchangeable and should not be selected from a travel package without specialist review.
Atrial fibrillation and sudden-death prevention require separate assessment
HCM can be complicated by atrial fibrillation and ventricular arrhythmias. Stroke-prevention and rhythm decisions for AF and sudden-cardiac-death risk stratification for possible ICD therapy are distinct parts of the pathway and should be assessed using the patient's clinical, imaging and rhythm profile.
Family assessment is part of HCM care
Because HCM is often inherited, a diagnosis can have implications for first-degree relatives. International patients should ask how genetic counselling, testing and family screening can be coordinated with cardiologists or genetics services in their home country rather than treating the German visit as an isolated procedure episode.
Sources and review
This guide was last source-reviewed on 2026-08-31.